Early antiretroviral treatment of infants to attain HIV remission

Louise Kuhn, Renate Strehlau, Stephanie Shiau, Faeezah Patel, Yanhan Shen, Karl-Günter Technau, Megan Burke, Gayle Sherman, Ashraf Coovadia, Grace M Aldrovandi, Rohan Hazra, Wei-Yann Tsai, Caroline T Tiemessen, Elaine J Abrams, LEOPARD Study Team, Louise Kuhn, Renate Strehlau, Stephanie Shiau, Faeezah Patel, Yanhan Shen, Karl-Günter Technau, Megan Burke, Gayle Sherman, Ashraf Coovadia, Grace M Aldrovandi, Rohan Hazra, Wei-Yann Tsai, Caroline T Tiemessen, Elaine J Abrams, LEOPARD Study Team

Abstract

Background: Studies in adults and children suggested that starting antiretroviral therapy (ART) soon after infection positively influences early events in HIV infection raising the possibility that remission may be achieved in some.

Methods: We designed an analytic treatment interruption (ATI) trial to test the hypothesis that a sizable minority of HIV-infected neonates who initiated ART <14 days of birth and maintained on ART would be able to maintain viral suppression when ART was withdrawn. To yield the target cohort for this trial, 73 HIV-infected neonates identified at one hospital in Johannesburg, South Africa, were initiated on ART <14 days of birth and maintained on ART tracking viral load (VL) decline and immune recovery (clinicaltrials.gov # NCT02431975).

Findings: Three HIV-infected infants (4.1%) died and nine (12.3%) were lost to follow-up before 48 weeks of age. Of those surviving on study, 52.5% attained and sustained VL <50 copies/ml and half of these sustained CD4+ T-cell percentage >30% which were the primary entry criteria for the ATI trial. Proportions achieving ATI eligibility criteria were similar in the 46 infants starting ART <48 h (19.6%) to 27 infants starting 2-14 days (25.9%) (p = 0.567).

Interpretation: Very early ART on its own, using regimens available when the trial was designed, is insufficient to attain minimum entry criteria needed to justify our trial of ART interruption. Decisions about how quickly to start ART should be based on optimizing standard clinical outcomes rather than with the expectation that remission can be attained.

Funding: NICHD/NIAID (U01HD080441), South African Research Chairs Initiative of DST and NRF (South Africa).

Keywords: Antiretroviral therapy; HIV; Neonate; Remission.

Conflict of interest statement

Drs. Kuhn, Technau and Coovadia report receiving grants from NIH. Dr. Abrams and Patel report receiving grants from NICHD. Dr. Burke reports receiving grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development/National Institute of Allergy and Infectious Disease, National Institutes of Health. Dr. Tiemessen reports receiving grants from the NIH and the South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation. The other authors have nothing to disclose.

© 2019 Published by Elsevier Ltd.

Figures

Fig. 1
Fig. 1
Flow diagram of screening to identify potential participants, their disposition prior to enrollment and follow-up after enrollment.
Fig. 2
Fig. 2
Viral load and other characteristics of the three study participants who died on study. P indicates the timing of positive diagnostic PCR tests.
Fig. 3
Fig. 3
Individual plots of viral load and CD4+ T-cell response to antiretroviral therapy of ten children in the study. P indicates the timing of positive, I indeterminate and N negative diagnostic PCR tests. A: Children who achieved and sustained target not detected and sustained CD4% >30% (3/61) B: Children who achieved and sustained target not detected but did not sustain CD4% >30% (7/61) C: Children who achieved and sustained 30% (13/61) D: Children who achieved and sustained 30% (9/61) E: Children who achieved 30% (6/61) F: Children who achieved 30% (8/61) G: Children who achieved and sustained 30% (1/61) H: Children who achieved and sustained 30% (1/61) I: Children who did not achieve 30% (3/61) J: Children who did not achieve 30% (10/61).
Fig. 3
Fig. 3
Individual plots of viral load and CD4+ T-cell response to antiretroviral therapy of ten children in the study. P indicates the timing of positive, I indeterminate and N negative diagnostic PCR tests. A: Children who achieved and sustained target not detected and sustained CD4% >30% (3/61) B: Children who achieved and sustained target not detected but did not sustain CD4% >30% (7/61) C: Children who achieved and sustained 30% (13/61) D: Children who achieved and sustained 30% (9/61) E: Children who achieved 30% (6/61) F: Children who achieved 30% (8/61) G: Children who achieved and sustained 30% (1/61) H: Children who achieved and sustained 30% (1/61) I: Children who did not achieve 30% (3/61) J: Children who did not achieve 30% (10/61).

References

    1. Saez-Cirion A., Bacchus C., Hocqueloux L., Avettand-Fenoel V., Girault I., Lecuroux C. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS visconti study. PLoS Pathog. 2013;9(3)
    1. Stohr W., Fidler S., McClure M., Weber J., Cooper D., Ramjee G. Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS ONE. 2013;8(10):e78287.
    1. Williams J.P., Hurst J., Stohr W., Robinson N., Brown H., Fisher M. HIV-1 DNA predicts disease progression and post-treatment virological control. Elife. 2014;3:e03821.
    1. Lodi S., Meyer L., Kelleher A.D., Rosinska M., Ghosn J., Sannes M. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med. 2012;172(16):1252–1255.
    1. Steingrover R., Pogany K., Fernandez Garcia E., Jurriaans S., Brinkman K., Schuitemaker H. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS. 2008;22(13):1583–1588.
    1. Namazi G., Fajnzylber J.M., Aga E., Bosch R.J., Acosta E.P., Sharaf R. The control of hiv after antiretroviral medication pause (CHAMP) study: posttreatment controllers identified from 14 clinical studies. J Infect Dis. 2018;218(12):1954–1963.
    1. Persaud D., Gay H., Ziemniak C., Chen Y.H., Piatak M., Jr., Chun T.W. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013;369(19):1828–1835.
    1. Tobin N.H., Aldrovandi G.M. Are infants unique in their ability to be “functionally cured” of HIV-1? Curr HIV/AIDS Rep. 2014;11(1):1–10.
    1. Goulder P.J., Lewin S.R., Leitman E.M. Paediatric hiv infection: the potential for cure. Nat Rev Immunol. 2016;16(4):259–271.
    1. Technau K.G., Kuhn L., Coovadia A., Murnane P.M., Sherman G. Xpert HIV-1 point-of-care test for neonatal diagnosis of hiv in the birth testing programme of a maternity hospital: a field evaluation study. The Lancet HIV. 2017;4(10):e442–e4e8.
    1. Avettand-Fenoel V., Hocqueloux L., Ghosn J., Cheret A., Frange P., Melard A., Viard J.P., Rouzioux C. Total HIV-1 DNA, a marker of viral reservoir dynamics with clinical implications. Clin Microbiol Rev. 2016;29(4):859–880.
    1. IMPAACT P1115 protocol: very early intensive treatment of HIV-infected infants to achieve remission: a phase I/II proof of concept study. 2018; (accessed 12 November 2019).
    1. Violari A., Cotton M.F., Gibb D.M., Babiker A.G., Steyn J., Madhi S.A. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359(21):2233–2244.
    1. Shiau S., Abrams E.J., Arpadi S.M., Kuhn L. Early antiretroviral therapy in HIV-infected infants: can it lead to HIV remission? The Lancet HIV. 2018;5(5):e250–e2e8.
    1. Marston M., Becquet R., Zaba B., Moulton L.H., Gray G., Coovadia H. Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan Africa. Int J Epidemiol. 2011;40(2):385–396.
    1. Rouzioux C., Costagliola D., Burgard M., Blanche S., Mayaux M.J., Griscelli C., Valleron A.J. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV infection in newborns french collaborative study group. Am J Epidemiol. 1995;142(12):1330–1337.
    1. Kelly C., Gaskell K.M., Richardson M., Klein N., Garner P., MacPherson P. Discordant immune response with antiretroviral therapy in HIV-1: a systematic review of clinical outcomes. PLoS ONE. 2016;11(6)
    1. Krogstad P., Patel K., Karalius B., Hazra R., Abzug M.J., Oleske J. Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents. Aids. 2015;29(6):683–693.
    1. European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord Prevalence and clinical outcomes of poor immune response despite virologically suppressive antiretroviral therapy among children and adolescents with HIV in Europe and Thailand: cohort study. Clin Infect Dis. 2019 An official publication of the Infectious Diseases Society of America Mar 28: pii.ciz253.
    1. Frange P., Faye A., Avettand-Fenoel V., Bellaton E., Descamps D., Angin M. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. The Lancet HIV. 2016;3(1):e49–e54.
    1. Violari A., Cotton M.F., Kuhn L., Schramm D.B., Paximadis M., Loubser S., Tiemessen C.T. A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. Nat Commun. 2019;10(1):412.
    1. Clarke D.F., Penazzato M., Capparelli E., Cressey T.R., Siberry G., Sugandhi N., Mirochnick M. Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. Expert Rev Clin Pharmacol. 2018;11(1):83–93.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa